ADMA Biologics Announces CFO Transition and Leadership Change

The latest update is out from ADMA Biologics ( (ADMA) ).

In 2025, ADMA Biologics delivered record financial results, with total revenue reaching $510 million, up 20% year over year, driven largely by a 51% surge in ASCENIV sales to $363 million and resulting in adjusted net income of $161 million and adjusted EBITDA of $231 million. On February 25, 2026, the company announced the retirement of Chief Financial Officer and Treasurer Brad Tade, effective February 25, 2026, with his transition to a paid consulting role through July 31, 2026, while veteran industry executive Terry Kohler assumes the CFO and Treasurer roles from February 26, 2026, under an employment agreement that includes equity grants, incentive compensation and change-of-control protections.

ADMA reiterated long-term financial guidance, forecasting 2026 revenue above $635 million and 2027 revenue above $775 million, and targeting more than $1.1 billion in annual revenue and at least $700 million in adjusted EBITDA in 2029, underscoring expectations for sustained double-digit growth and expanding margins. Operationally, the company highlighted yield-enhanced production now fully integrated into commercial operations, divestiture of three plasma centers for $12 million while securing long-term supply from over 280 third-party centers, and an expanded distribution agreement with McKesson Specialty, all aimed at improving capital efficiency, supply visibility and working capital.

Record ASCENIV utilization, supported by broad payer coverage, growing real-world evidence of reduced infections and hospitalizations, and ongoing medical education and direct-to-patient initiatives, is expected to continue driving demand and operating leverage beyond 2026. ADMA ended 2025 with about $88 million in cash, excluding pending plasma-center divestiture proceeds, and expects stronger cash generation and cost savings in 2026 to support growth investments, balance-sheet optimization and shareholder returns.

The most recent analyst rating on (ADMA) stock is a Buy with a $18.50 price target. To see the full list of analyst forecasts on ADMA Biologics stock, see the ADMA Stock Forecast page.

Spark’s Take on ADMA Stock

According to Spark, TipRanks’ AI Analyst, ADMA is a Outperform.

ADMA Biologics scores well due to its strong financial performance and positive earnings call, which highlight robust revenue growth and strategic initiatives for future expansion. The technical analysis suggests bullish momentum, though caution is advised due to overbought signals. Valuation is reasonable, supporting the overall positive outlook.

To see Spark’s full report on ADMA stock, click here.

More about ADMA Biologics

ADMA Biologics, Inc. is a U.S.-based, end-to-end commercial biopharmaceutical company focused on manufacturing, marketing and developing specialty biologics, including intravenous immunoglobulin therapies such as ASCENIV and BIVIGAM. The company targets patients with immunodeficiencies and related conditions, leveraging a vertically integrated manufacturing model and a diversified plasma supply network to support growth in the IVIG market.

In 2025, ADMA Biologics delivered record financial results, with total revenue reaching $510 million, up 20% year over year, driven largely by a 51% surge in ASCENIV sales to $363 million and resulting in adjusted net income of $161 million and adjusted EBITDA of $231 million. On February 25, 2026, the company announced the retirement of Chief Financial Officer and Treasurer Brad Tade, effective February 25, 2026, with his transition to a paid consulting role through July 31, 2026, while veteran industry executive Terry Kohler assumes the CFO and Treasurer roles from February 26, 2026, under an employment agreement that includes equity grants, incentive compensation and change-of-control protections.

ADMA reiterated long-term financial guidance, forecasting 2026 revenue above $635 million and 2027 revenue above $775 million, and targeting more than $1.1 billion in annual revenue and at least $700 million in adjusted EBITDA in 2029, underscoring expectations for sustained double-digit growth and expanding margins. Operationally, the company highlighted yield-enhanced production now fully integrated into commercial operations, divestiture of three plasma centers for $12 million while securing long-term supply from over 280 third-party centers, and an expanded distribution agreement with McKesson Specialty, all aimed at improving capital efficiency, supply visibility and working capital.

Record ASCENIV utilization, supported by broad payer coverage, growing real-world evidence of reduced infections and hospitalizations, and ongoing medical education and direct-to-patient initiatives, is expected to continue driving demand and operating leverage beyond 2026. ADMA ended 2025 with about $88 million in cash, excluding pending plasma-center divestiture proceeds, and expects stronger cash generation and cost savings in 2026 to support growth investments, balance-sheet optimization and shareholder returns.

Average Trading Volume: 2,305,018

Technical Sentiment Signal: Sell

Current Market Cap: $3.69B

For an in-depth examination of ADMA stock, go to TipRanks’ Overview page.